[go: up one dir, main page]

WO2005110460A3 - Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1) - Google Patents

Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1) Download PDF

Info

Publication number
WO2005110460A3
WO2005110460A3 PCT/US2005/014441 US2005014441W WO2005110460A3 WO 2005110460 A3 WO2005110460 A3 WO 2005110460A3 US 2005014441 W US2005014441 W US 2005014441W WO 2005110460 A3 WO2005110460 A3 WO 2005110460A3
Authority
WO
WIPO (PCT)
Prior art keywords
aging
muscle
diagnosis
treatment methods
methods related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/014441
Other languages
English (en)
Other versions
WO2005110460A2 (fr
Inventor
John J Kopchick
Karen T Coschigano
Keith S Boyce
Andres Kriete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Cogenics Icoria Inc
Original Assignee
Ohio University
Icoria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio University, Icoria Inc filed Critical Ohio University
Publication of WO2005110460A2 publication Critical patent/WO2005110460A2/fr
Publication of WO2005110460A3 publication Critical patent/WO2005110460A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une expression différente des gènes des souris en comparaison à l’expression des gènes selon l'âge des muscles des souris a été découverte et correspond aux gènes et protéines humaines. Les molécules humaines, ou antagonistes, peuvent être utilisées pour se protéger contre un vieillissement biologique plus rapide que la norme ou pour obtenir un vieillissement biologique plus lent que la norme. Les molécules humaines peuvent aussi être utilisées comme des indicateurs de vieillissement biologique.
PCT/US2005/014441 2004-04-29 2005-04-28 Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1) Ceased WO2005110460A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56606804P 2004-04-29 2004-04-29
US60/566,068 2004-04-29
US57793004P 2004-06-09 2004-06-09
US60/577,930 2004-06-09

Publications (2)

Publication Number Publication Date
WO2005110460A2 WO2005110460A2 (fr) 2005-11-24
WO2005110460A3 true WO2005110460A3 (fr) 2006-04-13

Family

ID=34969798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014441 Ceased WO2005110460A2 (fr) 2004-04-29 2005-04-28 Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1)

Country Status (1)

Country Link
WO (1) WO2005110460A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109540890A (zh) * 2018-11-27 2019-03-29 湖南品胜生物技术有限公司 一种基于细胞显微镜图像的dna定量分析方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
US20200141948A1 (en) * 2017-06-21 2020-05-07 Korea Research Institute Of Bioscience And Biotechnology Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker
CN113667739B (zh) * 2021-08-27 2023-12-26 河北医科大学第二医院 冠状动脉疾病的诊断标志物组合
EP4450970A1 (fr) * 2023-04-19 2024-10-23 Startquake S.L. Marqueurs d'horloge vieillissant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074911A2 (fr) * 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification des alterations de l'expression genetique qui accompagnent le processus de vieillissement des mammiferes
WO2003025122A2 (fr) * 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Biomarqueurs de profil d'expression genique et cibles therapeutiques destines au vieillissement cerebral et a la deficience intellectuelle liee a l'age

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074911A2 (fr) * 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification des alterations de l'expression genetique qui accompagnent le processus de vieillissement des mammiferes
WO2003025122A2 (fr) * 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Biomarqueurs de profil d'expression genique et cibles therapeutiques destines au vieillissement cerebral et a la deficience intellectuelle liee a l'age

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BODYAK NATALYA ET AL: "Gene expression profiling of the aging mouse cardiac myocytes", NUCLEIC ACIDS RESEARCH, vol. 30, no. 17, 1 September 2002 (2002-09-01), pages 3788 - 3794, XP002341760, ISSN: 0305-1048 *
BRONIKOWSKI A M ET AL: "Lifelong voluntary exercise in the mouse prevents age-related alterations in gene expression in the heart.", PHYSIOLOGICAL GENOMICS. 15 JAN 2003, vol. 12, no. 2, 15 January 2003 (2003-01-15), pages 129 - 138, XP002341762, ISSN: 1531-2267 *
LEE CHEOL-KOO ET AL: "Gene expression profile of aging and its retardation by caloric restriction", SCIENCE (WASHINGTON D C), vol. 285, no. 5432, 27 August 1999 (1999-08-27), pages 1390 - 1393, XP002341761, ISSN: 0036-8075 *
WEINDRUCH R ET AL: "Gene expression profiling of aging using DNA microarrays", MECHANISMS OF AGEING AND DEVELOPMENT, ELSEVIER SEQUOIA, LAUSANNE,, CH, vol. 123, 2002, pages 177 - 193, XP002304151, ISSN: 0047-6374 *
WEINDRUCH R ET AL: "Microarray profiling of gene expression in aging and its alteration by caloric restriction in mice", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 131, no. 3, March 2001 (2001-03-01), pages 918S - 923S, XP002961487, ISSN: 0022-3166 *
WELLE S ET AL: "Gene expression profile of aging in human muscle", PHYSIOLOGICAL GENOMICS 2003 UNITED STATES, vol. 14, 2003, pages 149 - 159, XP002341763, ISSN: 1531-2267 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109540890A (zh) * 2018-11-27 2019-03-29 湖南品胜生物技术有限公司 一种基于细胞显微镜图像的dna定量分析方法

Also Published As

Publication number Publication date
WO2005110460A2 (fr) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
WO2004076639A8 (fr) Compositions et methodes destinees a diagnostiquer et traiter des maladies auto-immunes
WO2004092405A3 (fr) Gene d'hemochromatose juvenile (hfe2a), produits d'expression et leurs utilisations
WO2006067122A3 (fr) Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes
WO2008060813A3 (fr) Anticorps antagonistes de haute affinité dirigés contre le récepteur alpha 1 de l'interleukine-13
BRPI0511479A (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
WO2008042231A3 (fr) Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
WO2007143090A3 (fr) Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
WO2008039566A3 (fr) Médicaments et utilisations
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2006124892A3 (fr) Modulateurs de la toxicite induite par l'alpha-synucleine
WO2005000335A3 (fr) Procedes de diagnostic et de traitement lies au vieillissement, en particulier au vieillissement du foie
WO2009106819A3 (fr) Matériaux biologiques et leurs utilisations
WO2004087965A3 (fr) Analyse statistique de sites de liaison de facteur regulateur de genes d'expression differentielle
WO2008049098A3 (fr) Antagonistes d'anticorps du récepteur α1 de l'interleukine-13
WO2005110460A3 (fr) Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1)
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
WO2004085614A3 (fr) Molecules d'acides nucleiques a regulation differentielle dans un trouble bipolaire et leurs utilisations
WO2009016231A3 (fr) Compositions et procédés permettant de détecter des troubles liés à l'histamine
EP2116616A3 (fr) Gènes exprimés differentiellement dans des cellules T activées et leurs utilisations
WO2005082398A3 (fr) Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires
WO2009021235A3 (fr) Procédés et compositions utilisables pour le traitement du cancer
WO2006122971A3 (fr) Traitement de maladies a l'aide d'un systeme d'expression regulee, ameliore
WO2004089982A3 (fr) Variantes april et leurs procedes
WO2008126517A1 (fr) Nouvelle protéine transporteuse de type slc17 dans un mammifère et son utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase